Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Akums Drugs and Pharmaceuticals Ltd
Other Operating Expenses
Akums Drugs and Pharmaceuticals Ltd
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
Other Operating Expenses
-₹558.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Other Operating Expenses
-₹15.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Other Operating Expenses
-₹7.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-16%
|
|
|
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
Other Operating Expenses
-₹6.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sai Life Sciences Ltd
NSE:SAILIFE
|
Other Operating Expenses
-₹1.3m
|
CAGR 3-Years
61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
Other Operating Expenses
-₹553.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Akums Drugs and Pharmaceuticals Ltd
Glance View
Akums Drugs and Pharmaceuticals Ltd., an unsung hero within India's healthcare sector, crafts its narrative through a robust commitment to pharmaceutical manufacturing. Founded in 2004, this company quietly emerged as a formidable provider of contract drug manufacturing solutions. Instead of marketing its own branded products, Akums positions itself as the silent partner behind many well-known pharmaceutical names, providing vital production services. By offering end-to-end manufacturing, from raw material sourcing to finished product packaging, Akums ensures that pharmaceutical companies can concentrate on their strengths: marketing and distribution. The company thrives on its vast portfolio, which encompasses the manufacture of nearly every form of a pharmaceutical product—be it tablets, capsules, injectables, or topical treatments. Akums drives revenue through partnerships, where it functions as the backbone of production lines for its clients. Utilizing cutting-edge technology and stringent global standards, Akums not only addresses the varied needs of the pharmaceutical industry but also adapts to the ever-evolving demands of healthcare worldwide. This strategic focus on high-quality contract manufacturing fuels its financial success, allowing it to expand facilities and scale operations, while maintaining a discreet presence that underscores its core philosophy: to innovate in service rather than spotlight.
See Also
What is Akums Drugs and Pharmaceuticals Ltd's Other Operating Expenses?
Other Operating Expenses
-558.7m
INR
Based on the financial report for Mar 31, 2025, Akums Drugs and Pharmaceuticals Ltd's Other Operating Expenses amounts to -558.7m INR.
What is Akums Drugs and Pharmaceuticals Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 1Y
6%
Over the last year, the Other Operating Expenses growth was 6%.